News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
NxStage Medical, Inc. Prices IPO At $13 To $15 For 5.5M Shares
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
9/22/2005. Underwriters for medical device company NxStage Medical Inc. set the terms of the company's pending initial public offering at 5.5 million shares with an estimated price range between $13 and $15 a share.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Drug Development
Dren Bio lands $350M to push rare blood cancer therapy toward market
October 29, 2026
·
2 min read
·
Gabrielle Masson
Immuno-oncology
Astellas bets up to $1.34B for option to advance Audax immuno-oncology asset
October 28, 2026
·
2 min read
·
Tristan Manalac
Podcast
Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
October 28, 2026
·
1 min read
·
Jef Akst
Business
US biotechs take lion’s share of $54.5B VC money raised since 2025
October 26, 2026
·
1 min read
·
Gabrielle Masson